Search

Displaying results 5361 - 5370 of 10000 in total
  1. Drug

    Tetrahydrofolic acid

    go.drugbank.com/drugs/DB00116
    InvestigationalNutraceutical

    It is converted into 5,10-methylenetetrahydrofolate by serine hydroxymethyltransferase. It is a soluble coenzyme in many reactions, especially in the metabolism of amino acids and nucleic acids. … Tetrahydrofolic acid is a folic acid derivative that is produced from dihydrofolic acid after conversion by dihydrofolate reductase.

  2. Drug

    HLX70

    go.drugbank.com/drugs/DB16509
    Investigational

    in healthy adult volunteers. … The condition targeted by HLX70 in this study is COVID-19.

  3. Drug

    N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine

    go.drugbank.com/drugs/DB13948
    Experimental

    It has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion [L1148]. It was discovered in 2014 at the University of Copenhagen. … 25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist.

    Synonyms: NBOH-2C-CN, N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine
  4. Drug

    Otamixaban

    go.drugbank.com/drugs/DB06635
    Investigational

    Otamixaban is a novel direct Factor Xa (FXa) inhibitor. It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.

  5. Drug

    Asvasiran

    go.drugbank.com/drugs/DB05638
    Investigational

    Asvasiran is an siRNA that targets the respiratory syncytial virus (RSV) N gene and inhibits viral replication. It has the potential to treat or prevent RSV infection.

  6. Drug

    Brasofensine

    go.drugbank.com/drugs/DB04857
    Experimental

    In November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230. … Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K.

  7. Drug

    Piretanide

    go.drugbank.com/drugs/DB02925
    Approved

    an aromatic nucleus in the presence of other aromatically bonded functional groups. … Piretanide (INN, trade names Arelix, Eurelix, Tauliz) has been synthesized in 1973 at Hoechst AG (Germany) as a loop diuretic compound by using a then-new method for introducing cyclic amine residues in

  8. Drug

    HSV-2 theracine

    go.drugbank.com/drugs/DB05811
    Experimental

    HSV-2 theracine is an attenuated recombinant vaccine developed by AuRx for the treatment of genital herpes.

  9. Drug

    Asoprisnil

    go.drugbank.com/drugs/DB06680
    Investigational

    Asoprisnil (J867) is a selective progesterone receptor modulator. It can be used to treat progesterone sensitive myomata.

  10. Drug

    Floctafenine

    go.drugbank.com/drugs/DB08976
    ApprovedWithdrawn

    Floctafenine is an anti-inflammatory analgesic similar in action to aspirin. Floctafenine inhibits prostaglandin synthesis.